Abstract
The major steps of the Analytic Phase will be described for IHC specifically, but in most cases the principles apply equally to ISH and IF methods that will be discussed in Chap. 14.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bogen SA. A root cause analysis into the high error rate in clinical immunohistochemistry. Appl Immunohistochem Mol Morph. 2019;27:329–38.
Canadian Biomarker Quality Assurance. Programme canadien d’assurance de la qualité des biomarqueurs. (n.d.). https://www.cbqa.ca/
Cartun R, Taylor CR. Techniques of immunohistochemistry: principles, pitfalls and standardization. In: Dabbs DJ, editor. Comprehensive diagnostic immunohistochemistry. 5th ed. Amsterdam: Elsevier; 2018.
Cheung CC, D’Arrigo C, Dietel M, et al. Evolution of quality assurance of clinical immunohistochemistry in the era of precision medicine—part 1: fit-for-purpose approach to classification of clinical immunohistochemistry tests. From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and international quality network for pathology (IQN path). Appl Immunohistochem Mol Morph. 2017a;25:4–11.
Cheung CC, D’Arrigo C, Dietel M, et al. Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine—part 4: tissue tools for quality assurance in immunohistochemistry. From the international society for immunohistochemistry and molecular morphology (ISIMM) and international quality network for pathology (IQN path). Appl Immunohistochem Mol Morph. 2017b;25:227–30.
European Parliament. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. 1998. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:1998:331:0001:0037:EN:PDF.
Hasan T, Carter B, Denic N, Gai L, Power J, Volsey K, Kao KR. Evaluation of cell-line-derived xenograft tumours as controls for immunohistochemical testing for ER and PR. J Clin Pathol. 2015;68:746–51. https://doi.org/10.1136/jclinpath-2015-203066.
Hewitt SM, Robinowitz M, Bogen SA, Gown AM, Kalra KL, Otis CN, Spaulding B, Taylor CR. Quality assurance for design control and implementation of immunohistochemistry assays: approved guidelines, vol. 31. 2nd ed. Wayne, PA: Clinical Lab Standards Institute; 2011. p. 4.
Kaur P, Ward B, Saha B, Young L, Groshen S, Techy G, Lu Y, Atkinson R, Taylor CR, Ingram M, Imam A. Human breast cancer Histioid: an in vitro 3D co-culture model that mimics breast tumor tissue. J Histochem Cytochem. 2011;59:1087–100.
Nass SJ, Phillips J, Patlak. Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies. National Cancer Policy Forum. Workshop Summary. The National Academies Press; 2015. NAP.edu/10766.
National Cancer Institute. NCI best practices for biospecimen resources. National Cancer Institute; 2016. https://biospecimens.cancer.gov/bestpractices/2016-NCIBestPractices.pdf
Nielsen S. External quality assessment for immunohistochemistry: experiences from NordiQC. Biotech Histochem. 2015;90:1–10. https://doi.org/10.3109/10520295.2015.1033462.
Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J, Taylor CR, Zhang X. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non small cell lung cancer. Appl Immunohistochem Mol Morph. 2015;23:541–9. https://doi.org/10.1097/PAI.0000000000000256.
Phillips T, Millett MM, Zhang X, Jansson M, Cleveland R, Simmons P, Cherryholmes G, Carnahan J, William J, Spaulding B, Satnick IR, Inzuna HD, Taylor CR, Cogswell J, Novotny J, Oroudjev E, Winther H. Development of a diagnostic programmed cell death 1-ligand 1 immunohistochemistry assay for Nivolumab therapy in melanoma. Appl Immunohistochem Mol Morph. 2018;26:6–12.
Taylor CR. Immunoperoxidase techniques: practical and theoretical aspects. Arch Pathol Lab Med. 1978;102:113–21.
Taylor CR. Quantitative in situ proteomics; a proposed pathway for quantification of immunohistochemistry at the light-microscopic level. Cell Tissue Res. 2015;360:109–20.
Taylor CR. Introduction to predictive biomarkers: definitions and characteristics. In: Badve S, Kumar G, editors. Predictive biomarkers in oncology: applications in precision medicine. Berlin: Springer Sciences; 2018.
Taylor CR, Burns J. The demonstration of plasma cells and other immunoglobulin- containing cells in formalin-fixed, paraffin-embedded tissues using peroxidase-labelled antibody. J Clin Pathol. 1974;27:14–20.
Taylor CR, Cote RJ, editors. Immunomicroscopy: a diagnostic tool for the surgical pathologist. 3rd ed. Saunders, Philadelphia: Elsevier; 2005. (1st edition, Taylor was 1986; 2nd edition, Taylor and Cote was 1994)
Taylor CR, Levenson RM. Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment. Histopathology. 2006;49:411–24.
Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu E, Swanson P, Taylor CR, Vyberg M. Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc committee. Appl Immunohistochem Mol Morph. 2014;22:241–52.
Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu E, Swanson P, Taylor CR, Vyberg M. Standardization of positive controls and introduction of immunohistochemistry critical assay performance controls (iCAPCs) in diagnostic immunohistochemistry: recommendations from the international ad hoc committee. Appl Immunohistochem Mol Morph. 2015;23:1–18.
Torlakovic EE, Cheung CC, D’Arrigo C, et al. Evolution of quality assurance of clinical immunohistochemistry in the era of precision medicine—part 2: immunohistochemistry test performance characteristics. From the international society for immunohistochemistry and molecular morphology (ISIMM) and international quality network for pathology (IQN path). Appl Immunohistochem Mol Morph. 2017a;25:79–85.
Torlakovic EE, Cheung CC, D’Arrigo C, et al. Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine—part 3: technical validation of immunohistochemistry (IHC) assays in clinical IHC laboratories. From the international society for immunohistochemistry and molecular morphology (ISIMM) and international quality network for pathology (IQN path). Appl Immunohistochem Mol Morph. 2017b;25:151–9.
U.S. Food and Drug Administration. Guidance for industry and FDA staff. In vitro diagnostic (IVD) device studies—frequently asked questions. 2010. http://www.fda.gov/downloads/MedicalDevices/…/ucm071230.pdf.
U.S. Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). 2021. Other nucleic acid based tests are listed separately under an included link. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm. Accessed 2 Apr 2021.
Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunol Ther Cancer. 2016;4:3.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jasani, B., Huss, R., Taylor, C.R. (2021). Analytical Phase: Principles for Immunohistochemistry (IHC). In: Precision Cancer Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-84087-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-84087-7_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-84086-0
Online ISBN: 978-3-030-84087-7
eBook Packages: MedicineMedicine (R0)